Placebo News and Research

RSS

High-flow oxygen appears to be more effective in treating cluster headaches

Patients with a cluster headache, which is characterized by bouts of excruciating pain usually near the eye or temple, were more likely to report being pain-free within 15 minutes of treatment with high-flow oxygen than patients who received a placebo treatment, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

9 Dec 2009

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.

9 Dec 2009

Progenitor-cell therapy can reduce risk of another heart attack

Cells from heart attack survivors' own bone marrow reduced the risk of death or another heart attack when they were infused into the affected artery after successful stent placement, according to research reported in the American Heart Association journal Circulation: Heart Failure.

9 Dec 2009

New findings suggest Ginkgo extract can improve cognitive functions

"Ginkgo biloba not only improves declining memory but offers specific benefits for other cognitive functions as well" that's how Dr. Reiner Kaschel, Clinical Neuropsychologist at the University of Osnabrueck, Germany, summarizes the results of a comprehensive new scientific publication.

9 Dec 2009

BHR Pharma files an IND for its BHR-100 intravenous progesterone infusion product

BHR Pharma, LLC (BHR) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its proprietary BHR-100 intravenous progesterone infusion product.

8 Dec 2009

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Vitamins and nutriceuticals improve memory and cognitive performance, shows study

A recent study presented at the Gerontological Society of America's 62nd Annual Scientific Meeting shows that a combination of vitamins and nutriceuticals improves memory and cognitive performance in community-dwelling adults.

8 Dec 2009

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).

8 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

Selenium-based antioxidant compound reduces risk of colorectal cancer

Supplementation with a selenium-based antioxidant compound decreased the risk of developing new polyps of the large bowel — called colorectal metachronous adenomas — in people who previously had colorectal polyps removed.

8 Dec 2009

Individuals taking antidepressants may experience personality change, says new report

Individuals taking a medication to treat depression may experience changes in their personality separate from the alleviation of depressive symptoms, according to a report in the December issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Dec 2009

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

7 Dec 2009

UCB presents data on Vimpat AED at AES meeting

UCB today announced new findings on its antiepileptic drug (AED) Vimpat® that offer additional clinical evidence supporting the use of this AED as adjunctive therapy in adult patients with partial-onset seizures. Results of presented research demonstrate sustained efficacy in adult patients taking Vimpat® for up to three years, and a consistent long-term tolerability profile.

7 Dec 2009

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

TaiGen Biotechnology Co., Ltd. announced today the presentation of Phase I and preclinical data for TG-0054, the Company's chemokine receptor CXCR4 antagonist and a novel, potent stem cell mobilizer, at the ASH Annual Meeting held in New Orleans, the US, from December 5 to 8, 2009.

7 Dec 2009

J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD), announced today that results from the Phase III EINSTEIN-Extension (EXT) clinical trial of the novel oral anticoagulant rivaroxaban showed a significant reduction in the risk of recurrent symptomatic venous thromboembolism (VTE), compared to placebo, in patients who have been treated for a previous deep vein thrombosis (DVT) or pulmonary embolism (PE).

7 Dec 2009

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolve naturally, a potentially life-threatening situation requiring treatment.

7 Dec 2009

Placebo News and Research

High-flow oxygen appears to be more effective in treating cluster headaches

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

Progenitor-cell therapy can reduce risk of another heart attack

New findings suggest Ginkgo extract can improve cognitive functions

BHR Pharma files an IND for its BHR-100 intravenous progesterone infusion product

Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Vitamins and nutriceuticals improve memory and cognitive performance, shows study

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Amgen announces results from first Phase 1/2 study of Nplate

Selenium-based antioxidant compound reduces risk of colorectal cancer

Individuals taking antidepressants may experience personality change, says new report

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

UCB presents data on Vimpat AED at AES meeting

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

J&JPRD announces clinical results of new oral anticoagulant therapy for venous thromboembolism

Anticoagulants used to prevent clots in placental blood vessels ineffective, reveals research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News